The medical establishment classifies cancer as a collection of more than 200 related diseases. The pharmaceutical industry treats it as such — developing targeted drugs for each variant, each with its own price tag, each with its own clinical trial pipeline. But a growing body of researchers, authors, and practitioners are asking a question that the mainstream framework does not accommodate easily: what if cancer is not a disease at all, but a biological process — one that the body itself initiates, and one that the body may, under certain conditions, be capable of reversing?
The distinction is not semantic. It determines how billions of dollars are spent, how millions of patients are treated, and whether alternative approaches receive serious scientific investigation or are dismissed as fringe.
Why Cancer Is Classified as a Group of Diseases
In conventional medical terminology, cancer is not one illness but a term encompassing over 200 different conditions — carcinomas, sarcomas, leukemias, lymphomas, and others. Each behaves differently, responds to different treatments, and arises from different genetic mutations.
At its core, the medical definition describes cancer as a genetic disease caused by changes to genes that control how cells function, grow, and divide. The result is uncontrolled growth — abnormal cells that divide without restraint and infiltrate surrounding tissue. Because each type is genetically distinct, a treatment that works for breast cancer may be ineffective against lung cancer, and what addresses leukemia may have no impact on melanoma.
This framework has produced genuine advances. Targeted therapies, immunotherapies, and precision medicine have improved survival rates for specific cancers significantly over the past two decades. The framework is not without merit.
But it is not the only framework.
The Phenomenon Perspective
George Johnson, in The Cancer Chronicles, argues that because cancer arises from our own cells “going rogue” — rather than from a foreign invader like bacteria or a virus — it is more accurately described as a phenomenon than a disease in the traditional sense.
This perspective reframes the entire conversation. Cancer cells are not foreign entities. They are the body’s own cells that have developed survival advantages — cells that have, in a sense, remembered how to grow without limits, a capability that all cells possessed in the earliest stages of embryonic development.
The process typically takes years. Mutations accumulate gradually. The immune system handles most aberrant cells successfully for decades. What we call “cancer” is the point at which the balance tips — when the body’s surveillance systems can no longer contain cells that have acquired the ability to evade detection and suppression.
If this framing is accurate, then the question shifts from “how do we kill these cells?” to “what caused the body’s regulatory systems to fail, and can they be restored?”
Why This Distinction Matters
The “not one disease” framework has a practical implication that researchers themselves acknowledge: there will never be a single “magic bullet” cure. Each of the 200+ variants requires its own approach, its own drug, its own clinical pathway. This is convenient for an industry that profits from complexity and specificity, but it may obscure a simpler underlying reality.
If cancer is a process — a systemic failure of cellular regulation — then addressing the systemic conditions that enable it may be as important as targeting the individual cells that result from it. This is where conventional and alternative approaches diverge most sharply.
Alternative and Emerging Approaches
Outside the conventional oncology framework, a range of approaches have attracted attention — some with preliminary research support, others with anecdotal evidence that the medical establishment has been reluctant to investigate rigorously.
Fenbendazole: Originally developed as an anti-parasitic drug for animals, fenbendazole gained public attention after Joe Tippens, an Oklahoma man diagnosed with terminal small cell lung cancer, reported complete remission after taking the drug alongside vitamin E, curcumin, and CBD oil. His case, widely shared online, prompted researchers to examine fenbendazole’s mechanism of action. Studies have shown that fenbendazole disrupts microtubule formation in cancer cells — a mechanism similar to certain chemotherapy drugs like taxol — while appearing to have significantly fewer side effects. Peer-reviewed research published in Scientific Reports (Nature) has confirmed anti-tumor activity in laboratory settings. Despite this, no large-scale clinical trials have been conducted.
Ivermectin: Another anti-parasitic medication that has shown anti-cancer properties in laboratory studies. Research published in the American Journal of Cancer Research documented ivermectin’s ability to inhibit tumor growth through multiple pathways, including inducing mitochondrial dysfunction in cancer cells. Like fenbendazole, it remains largely uninvestigated in clinical oncology trials.
Metabolic Therapy: Dr. Thomas Seyfried of Boston College has advanced the theory that cancer is fundamentally a metabolic disease — a disorder of cellular energy production — rather than a genetic disease. His research suggests that cancer cells are dependent on glucose fermentation (the Warburg effect) and that restricting glucose availability through ketogenic diets and caloric restriction can starve cancer cells while normal cells adapt to using ketone bodies for fuel. His work, published in peer-reviewed journals, challenges the genetic mutation theory that underpins most of modern oncology.
High-Dose Vitamin C: Intravenous vitamin C therapy, pioneered by Linus Pauling and now studied at institutions including the University of Iowa, has shown the ability to generate hydrogen peroxide in tumor tissue, selectively damaging cancer cells while leaving healthy cells intact. Several clinical trials are ongoing.
Hyperthermia: The use of controlled heat to damage cancer cells has been practiced in Germany, Japan, and other countries for decades. Cancer cells are more vulnerable to heat than normal cells due to their disorganized blood supply. Hyperthermia is increasingly being combined with conventional treatments in European oncology centers.
Immunotherapy and the Microbiome: Emerging research has demonstrated that the gut microbiome plays a significant role in cancer development and treatment response. Patients with diverse gut bacteria respond better to immunotherapy. Fecal microbiota transplants are being studied as adjuncts to cancer treatment — a concept that would have been dismissed as absurd a decade ago.
The Pattern
There is a pattern in how alternative cancer approaches are handled by the medical establishment. Individual cases of remission are dismissed as anecdotal. Laboratory studies showing efficacy are acknowledged but not funded for clinical trials. Drugs that are off-patent and inexpensive — fenbendazole costs pennies per dose — do not attract pharmaceutical investment because they cannot be patented and sold at oncology prices.
The question is not whether any single alternative approach is a proven cure. It is whether the current framework — which classifies cancer as 200 separate genetic diseases requiring 200 separate expensive treatments — is the only valid framework, or whether it exists in part because it is the most profitable one.
The researchers who describe cancer as a phenomenon rather than a disease are not denying its lethality. They are suggesting that the lens through which we examine it determines what solutions we are capable of seeing. A process can be interrupted. A systemic failure can be addressed systemically. A phenomenon can be understood and managed.
Whether the medical establishment is willing to pursue these questions with the same resources and urgency it dedicates to patentable treatments is a matter of institutional incentive, not scientific impossibility.
